Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Investing Activities: 2022-2025

Historic Cash from Investing Activities for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $13.5 million.

  • Day One Biopharmaceuticals' Cash from Investing Activities rose 119.88% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$262.5 million, marking a year-over-year decrease of 480.25%. This contributed to the annual value of -$231.0 million for FY2024, which is 279.93% down from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Cash from Investing Activities stood at $13.5 million for Q3 2025, which was down 48.86% from $26.3 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Cash from Investing Activities peaked at $89.3 million during Q1 2024, and registered a low of -$269.6 million during Q4 2024.
  • Its 3-year average for Cash from Investing Activities is -$8.7 million, with a median of $17.1 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Day One Biopharmaceuticals' Cash from Investing Activities was 1,474.66% (2023), while the steepest drop was 74,520.00% (2023).
  • Day One Biopharmaceuticals' Cash from Investing Activities (Quarterly) stood at -$2.2 million in 2022, then spiked by 1,474.66% to $30.4 million in 2023, then tumbled by 987.56% to -$269.6 million in 2024, then soared by 119.88% to $13.5 million in 2025.
  • Its last three reported values are $13.5 million in Q3 2025, $26.3 million for Q2 2025, and -$32.6 million during Q1 2025.